Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive
NCT03790397
·
clinicaltrials.gov ↗
COMPLETED
Status
169
Enrollment
OTHER
Sponsor class
Conditions
Non Small Cell Lung Cancer
Interventions
DRUG:
Osimertinib
Sponsor
Fundación GECP